Compare HMY & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMY | PEN |
|---|---|---|
| Founded | 1950 | 2004 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 12.2B |
| IPO Year | N/A | 2015 |
| Metric | HMY | PEN |
|---|---|---|
| Price | $21.23 | $359.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 18 |
| Target Price | $16.00 | ★ $350.94 |
| AVG Volume (30 Days) | ★ 4.5M | 1.6M |
| Earning Date | 02-04-2016 | 02-17-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | 67.74 | ★ 367.34 |
| EPS | 1.29 | ★ 4.14 |
| Revenue | ★ $4,161,584,110.00 | $1,333,798,000.00 |
| Revenue This Year | $40.10 | $17.03 |
| Revenue Next Year | $14.83 | $14.38 |
| P/E Ratio | ★ $19.43 | $86.27 |
| Revenue Growth | ★ 20.39 | 14.61 |
| 52 Week Low | $9.69 | $221.26 |
| 52 Week High | $26.06 | $362.41 |
| Indicator | HMY | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 71.46 |
| Support Level | $23.04 | $356.39 |
| Resistance Level | $26.04 | $361.05 |
| Average True Range (ATR) | 1.22 | 7.48 |
| MACD | 0.00 | 0.91 |
| Stochastic Oscillator | 4.46 | 96.44 |
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.